Cogent Biosciences (COGT) Free Cash Flow (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Free Cash Flow data on file, last reported at -$87.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 30.23% year-over-year to -$87.3 million in Q1 2026; TTM through Mar 2026 was -$286.3 million, a 28.48% decrease from a year earlier, with the FY2025 full-year figure at -$266.0 million, down 27.66% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$87.3 million, down from -$79.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for COGT reached as high as -$27.6 million in Q2 2022 and fell as low as -$87.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$49.6 million across 5 years, with a median of -$44.4 million in 2023.
• Across the five-year window, Free Cash Flow plunged 153.17% in 2022 and fell 0.9% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$31.4 million in 2022, then sank by 41.47% to -$44.4 million in 2023, then tumbled by 36.65% to -$60.7 million in 2024, then slumped by 31.76% to -$79.9 million in 2025, then slipped by 9.28% to -$87.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$87.3 million in Q1 2026, -$79.9 million in Q4 2025, and -$64.4 million in Q3 2025.